Probleme bei der Darstellung von ARIVA.DE?

  • Laden unsere Charts bei Ihnen nicht?
  • Wird unser Forum bei Ihnen nicht korrekt dargestellt?

Sie nutzen einen Adblocker, der hierfür verantwortlich ist. Hierauf hat ARIVA.DE leider keinen Einfluss. Bitte heben Sie die Blockierung von ARIVA.DE in Ihrem Adblocker auf.

Probleme bei der Darstellung von ARIVA.DE?

Valeant Announces Third Quarter Financial Results Date And Conference Call Details

Montag, 17.10.2016 18:20 von

PR Newswire

LAVAL, Quebec, Oct. 17, 2016 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that it plans to release third quarter 2016 financial results on Tuesday, November 8, 2016, prior to the conference call and live webcast at 8:00 a.m. ET, when the Company will discuss the results.

Conference Call Details



Date

Tuesday, November 8, 2016

Time

8:00 a.m. ET

Webcast

http://ir.valeant.com/events-and-presentations

Participant Event Dial-in 

(877) 876-8393 (North America)


(973) 200-3961 (International) 

Participant Passcode

49468113

Replay Dial-in

(855) 859-2056 (North America)


(404) 537-3406 (International) 

Replay Passcode

49468113 (replay available until November 16, 2016)

About Valeant
Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, gastrointestinal disorders, eye health, neurology and branded generics. More information about Valeant can be found at www.valeant.com.

Contact Information:
Elif McDonald
elif.mcdonald@valeant.com
514-856-3855
877-281-6642 (toll free)

Media:
Renée Soto
or
Chris Kittredge/Jared Levy
Sard Verbinnen & Co.
212-687-8080

Valeant Pharmaceuticals International, Inc.

Logo - http://photos.prnewswire.com/prnh/20101025/LA87217LOGO

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/valeant-announces-third-quarter-financial-results-date-and-conference-call-details-300345912.html

SOURCE Valeant Pharmaceuticals International, Inc.